
<!DOCTYPE html>
<html>
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<meta http-equiv="X-UA-Compatible" content="ie=edge">
<title>Markmap</title>
<style>
* {
  margin: 0;
  padding: 0;
}
#mindmap {
  display: block;
  width: 100vw;
  height: 100vh;
}
</style>
<link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/markmap-toolbar@0.17.0/dist/style.css">
<link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/katex@0.16.8/dist/katex.min.css">
</head>
<body>
<svg id="mindmap"></svg>
<script src="https://cdn.jsdelivr.net/npm/d3@7.8.5/dist/d3.min.js"></script>
<script src="https://cdn.jsdelivr.net/npm/markmap-view@0.17.0/dist/browser/index.js"></script>
<script src="https://cdn.jsdelivr.net/npm/markmap-toolbar@0.17.0/dist/index.js"></script>
<script>
window.WebFontConfig = {
  custom: {
    families: [
      "KaTeX_AMS","KaTeX_Caligraphic:n4,n7","KaTeX_Fraktur:n4,n7",
      "KaTeX_Main:n4,n7,i4,i7","KaTeX_Math:i4,i7","KaTeX_Script",
      "KaTeX_SansSerif:n4,n7,i4","KaTeX_Size1","KaTeX_Size2",
      "KaTeX_Size3","KaTeX_Size4","KaTeX_Typewriter"
    ],
    active: function() {
      window.markmap.refreshHook.call();
    }
  }
};
</script>
<script src="https://cdn.jsdelivr.net/npm/webfontloader@1.6.28/webfontloader.js" defer></script>
<script>
(() => {
  setTimeout(() => {
    const { markmap: Markmap, mm: markmapInstance } = window;
    const toolbar = new Markmap.Toolbar();
    toolbar.attach(markmapInstance);
    const toolbarElement = toolbar.render();
    toolbarElement.style.position = 'absolute';
    toolbarElement.style.bottom = '20px';
    toolbarElement.style.right = '20px';
    document.body.append(toolbarElement);
  });

  ((getMarkmap, getOptions, root, jsonOptions) => {
    const markmap = getMarkmap();
    window.mm = markmap.Markmap.create(
      "svg#mindmap",
      (getOptions || markmap.deriveOptions)(jsonOptions),
      root
    );
  })(() => window.markmap, null, {"content":"BCM Breast Cancer Trials","children":[{"content":"MED ONC","children":[{"content":"Adjuvant","children":[{"content":"HER2","children":[{"content":"NO LINE","children":[{"content":"<strong>FLAMINGO -01</strong>","children":[{"content":"Stage I/II with nonpCR OR stage III (pCR or not) to be enorlled &lt;90 days from completion of HP/TDM1 * TWO cohorst depending on HLA-A*02","children":[],"payload":{"lines":"5,6"}}],"payload":{"lines":"4,6"}},{"content":"<strong>CompassHER2 RD</strong>","children":[{"content":"Prior NACT with 6 or more cycles of chemo (at least 9 weeks or THP). If was part of EA1181, must receive 2 more cycles of chemo * ER+ must be ypN+ (1/2/3) with ypT1/2/3. Weak ER+ can be ypN0. Will be randomized to TDM1 vs TDM1 and Tucatinib. May receive ≤ 1 cycle adjuvant T-DM1 prior to registration","children":[],"payload":{"lines":"7,8"}}],"payload":{"lines":"6,8"}},{"content":"<strong>CompassHER2 RD</strong>","children":[{"content":"Prior NACT with 6 or more cycles of chemo (at least 9 weeks or THP). If was part of EA1181, must receive 2 more cycles of chemo * ER- can be ypT1/2/3 with ypN0/1/2/3. Will be randomized to TDM1 vs TDM1 and Tucatinib. May receive ≤ 1 cycle adjuvant T-DM1 prior to registration","children":[],"payload":{"lines":"9,10"}}],"payload":{"lines":"8,10"}},{"content":"<strong>ICE COMPRESS / SWOG S2205</strong>","children":[{"content":"NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere). * Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's","children":[],"payload":{"lines":"11,12"}}],"payload":{"lines":"10,12"}}],"payload":{"lines":"3,12"}}],"payload":{"lines":"2,12"}},{"content":"HR POS","children":[{"content":"NO LINE","children":[{"content":"<strong>CAMBRIA-1</strong>","children":[{"content":"Intermediate and High risk to randomize between adjuvant year 2 : 5 to either continue adj. ET SoC vs oral SERD * Intermediate: T3 N0 | T1c/T2 N1 [2-3 LN] | T1c/T2 N0 (Grade III, KI67 &gt;= 20%, LumB/RS26, or prior chemotherapy) * High: Stage III | T1c/T2 N1 [2-3] (Grade III, KI67 &gt;= 20%, LumB/RS26) | T1c/T2 N1 [1/3] (Grade III, KI67 &gt;= 20%, LumB/RS26)","children":[],"payload":{"lines":"15,16"}}],"payload":{"lines":"14,16"}},{"content":"<strong>ICE COMPRESS / SWOG S2205</strong>","children":[{"content":"NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere). * Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's","children":[],"payload":{"lines":"17,18"}}],"payload":{"lines":"16,18"}},{"content":"<strong>OFSET (NRG BR009)</strong>","children":[{"content":"ER+ (&gt;1%) HER2- with pT1-3 pN0-1. * RS N1 &lt;26. RS N0 21-25. RS N0 16-20 WITH T minimum at 30mm (G1), 20mm (G2) or 10mm (G3)","children":[],"payload":{"lines":"19,20"}}],"payload":{"lines":"18,20"}}],"payload":{"lines":"13,20"}}],"payload":{"lines":"12,20"}},{"content":"TNBC","children":[{"content":"NO LINE","children":[{"content":"<strong>ICE COMPRESS / SWOG S2205</strong>","children":[{"content":"NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere). * Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's","children":[],"payload":{"lines":"23,24"}}],"payload":{"lines":"22,24"}},{"content":"<em>Optimize-PCR (A012103)</em>","children":[{"content":"TNBC (&lt;10%) T1cN1-2 or T2-4N0-2 with ypT0 OR ypTis * Adju RT and Pembro, followed by registration","children":[],"payload":{"lines":"25,26"}}],"payload":{"lines":"24,26"}},{"content":"<em>ASCENT-05</em>","children":[{"content":"TNBC (&lt;10%) with residual disease","children":[],"payload":{"lines":"27,28"}}],"payload":{"lines":"26,28"}}],"payload":{"lines":"21,28"}}],"payload":{"lines":"20,28"}}],"payload":{"lines":"1,28"}},{"content":"Metastatic","children":[{"content":"HER2","children":[{"content":"1","children":[{"content":"STOPHER2 / TBCRC 062","children":[{"content":"On 1st Line ABC HER2+ for 3 or more years. If brain disease, has to be stable for 2 or more years * Continue ET therapy. Can be enrolled if ET was changed","children":[],"payload":{"lines":"32,33"}}],"payload":{"lines":"31,33"}},{"content":"STOPHER2 / TBCRC 062","children":[{"content":"On 1st Line ABC HER2+ for 3 or more years. If brain disease, has to be stable for 2 or more years","children":[],"payload":{"lines":"34,35"}}],"payload":{"lines":"33,35"}}],"payload":{"lines":"30,35"}},{"content":"2","children":[{"content":"<strong>VISTA</strong>","children":[{"content":"HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA) * Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.","children":[],"payload":{"lines":"37,38"}}],"payload":{"lines":"36,38"}}],"payload":{"lines":"35,38"}},{"content":"3","children":[{"content":"<strong>VISTA</strong>","children":[{"content":"HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA) * Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.","children":[],"payload":{"lines":"40,41"}}],"payload":{"lines":"39,41"}}],"payload":{"lines":"38,41"}},{"content":"4","children":[{"content":"<strong>VISTA</strong>","children":[{"content":"HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA) * Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.","children":[],"payload":{"lines":"43,44"}}],"payload":{"lines":"42,44"}}],"payload":{"lines":"41,44"}}],"payload":{"lines":"29,44"}},{"content":"HR POS","children":[{"content":"1","children":[{"content":"<em>EvoPAR-Breast01</em>","children":[{"content":"DenoVo metastatic opr 1ry resistant ER+ (&gt;1%) * BRCA1/2 OR PALB2 (either germline or somatic)","children":[],"payload":{"lines":"47,48"}}],"payload":{"lines":"46,48"}}],"payload":{"lines":"45,48"}},{"content":"2","children":[{"content":"<strong>ELAINE-III</strong>","children":[{"content":"Progression on 1st Line CDK4/6. ESR1 mutation","children":[],"payload":{"lines":"50,51"}}],"payload":{"lines":"49,51"}},{"content":"<em>OPERA-1</em>","children":[{"content":"Post 1st Line progression while on ET/CDK , adjuvant ET or within 2 years post ET. No prior Chemo in Stage 4. * Part A three arm for OP 120, OP 90 and SoC. Part B is OP vs SoC [Faslo or AI]","children":[],"payload":{"lines":"52,53"}}],"payload":{"lines":"51,53"}},{"content":"<strong>VISTA</strong>","children":[{"content":"HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA) * Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.","children":[],"payload":{"lines":"54,55"}}],"payload":{"lines":"53,55"}}],"payload":{"lines":"48,55"}},{"content":"3","children":[{"content":"<em>OPERA-1</em>","children":[{"content":"Post 2 Lines Line of ET, lasting at least 6 months. No prior Chemo in Stage 4. * Part A three arm for OP 120, OP 90 and SoC. Part B is OP vs SoC [Faslo or AI] * If 2nd line was Faslo, 3rd line SoC can be AI","children":[],"payload":{"lines":"57,58"}}],"payload":{"lines":"56,58"}},{"content":"<strong>VISTA</strong>","children":[{"content":"HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA) * Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.","children":[],"payload":{"lines":"59,60"}}],"payload":{"lines":"58,60"}}],"payload":{"lines":"55,60"}},{"content":"4","children":[{"content":"<strong>VISTA</strong>","children":[{"content":"HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA) * Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.","children":[],"payload":{"lines":"62,63"}}],"payload":{"lines":"61,63"}}],"payload":{"lines":"60,63"}}],"payload":{"lines":"44,63"}},{"content":"TNBC","children":[{"content":"2","children":[{"content":"<strong>VISTA</strong>","children":[{"content":"HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA) * Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.","children":[],"payload":{"lines":"66,67"}}],"payload":{"lines":"65,67"}}],"payload":{"lines":"64,67"}},{"content":"3","children":[{"content":"<strong>VISTA</strong>","children":[{"content":"HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA) * Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.","children":[],"payload":{"lines":"69,70"}}],"payload":{"lines":"68,70"}}],"payload":{"lines":"67,70"}},{"content":"4","children":[{"content":"<strong>VISTA</strong>","children":[{"content":"HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA) * Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.","children":[],"payload":{"lines":"72,73"}}],"payload":{"lines":"71,73"}}],"payload":{"lines":"70,73"}}],"payload":{"lines":"63,73"}}],"payload":{"lines":"28,73"}},{"content":"Neoadjuvant","children":[{"content":"HER2","children":[{"content":"NO LINE","children":[{"content":"<strong>RESPONSE</strong>","children":[{"content":"1ry 20mm or more (T2 N0 and higher) by exam or imaging. Excludes IBC and BL cancers * Will receive weekly Taxol HP with ddAC","children":[],"payload":{"lines":"77,78"}}],"payload":{"lines":"76,78"}},{"content":"<strong>ICE COMPRESS / SWOG S2205</strong>","children":[{"content":"NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere). * Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's","children":[],"payload":{"lines":"79,80"}}],"payload":{"lines":"78,80"}}],"payload":{"lines":"75,80"}}],"payload":{"lines":"74,80"}},{"content":"HR POS","children":[{"content":"NO LINE","children":[{"content":"<strong>RESPONSE</strong>","children":[{"content":"1ry 20mm or more (T2 N0 and higher) by exam or imaging. Excludes IBC and BL cancers * High Risk ER+ (Grade III, Age &lt;50, ER &lt; 6/8 OR Ki67 &gt;29%). Will receive weekly Taxol with ddAC","children":[],"payload":{"lines":"83,84"}}],"payload":{"lines":"82,84"}},{"content":"<strong>TBCRC042</strong>","children":[{"content":"ADH, ALH, LCIS or DCIS requiring excision. T1(mi) is allowed. If undergoing germline testing, results should be available prior to randomization * Ruxo vs Placebo for 15 days +/- 5 days. Surgery within 12 hours of last dose","children":[],"payload":{"lines":"85,86"}}],"payload":{"lines":"84,86"}},{"content":"<em>EVANGELINE</em>","children":[{"content":"Clinical T2 or T3 and N0 or N1 with Grade I and II * ER+ 67% or more, Allred 6-8","children":[],"payload":{"lines":"87,88"}}],"payload":{"lines":"86,88"}},{"content":"TBCRC 037","children":[{"content":"ILC ER+ POSTmenopausal. Tumor 10mm or more. No HRT in prior 2 years","children":[],"payload":{"lines":"89,90"}}],"payload":{"lines":"88,90"}},{"content":"<strong>ICE COMPRESS / SWOG S2205</strong>","children":[{"content":"NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere). * Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's","children":[],"payload":{"lines":"91,92"}}],"payload":{"lines":"90,92"}},{"content":"<em>NCBRE</em>","children":[{"content":"ILC ER+ PR+ HER2- with ERBB2 mutation. * T1c (Min size 15mm) N0/N1/N2","children":[],"payload":{"lines":"93,94"}}],"payload":{"lines":"92,94"}},{"content":"<em>S2206</em>","children":[{"content":"High 2 on MP","children":[],"payload":{"lines":"95,96"}}],"payload":{"lines":"94,96"}}],"payload":{"lines":"81,96"}}],"payload":{"lines":"80,96"}},{"content":"TNBC","children":[{"content":"NO LINE","children":[{"content":"<strong>RESPONSE</strong>","children":[{"content":"1ry 20mm or more (T2 N0 and higher) by exam or imaging. Excludes IBC and BL cancers * Will receive weekly Taxol with ddAC (Pembro added if indicated, Carbo added if T3)","children":[],"payload":{"lines":"99,100"}}],"payload":{"lines":"98,100"}},{"content":"<strong>TBCRC042</strong>","children":[{"content":"ADH, ALH, LCIS or DCIS requiring excision. T1(mi) is allowed. If undergoing germline testing, results should be available prior to randomization * Ruxo vs Placebo for 15 days +/- 5 days. Surgery within 12 hours of last dose","children":[],"payload":{"lines":"101,102"}}],"payload":{"lines":"100,102"}},{"content":"<strong>ICE COMPRESS / SWOG S2205</strong>","children":[{"content":"NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere). * Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's","children":[],"payload":{"lines":"103,104"}}],"payload":{"lines":"102,104"}},{"content":"<em>S2212</em>","children":[{"content":"TNBC (&lt;5%) with T2-T4 N0 OR T1-T3 N1-N2. * No Stage IIIC, IIIB T4 N+ OR IBC","children":[],"payload":{"lines":"105,106"}}],"payload":{"lines":"104,106"}}],"payload":{"lines":"97,106"}}],"payload":{"lines":"96,106"}}],"payload":{"lines":"73,106"}}],"payload":{"lines":"0,106"}},{"content":"RAD ONC","children":[{"content":"Adjuvant","children":[{"content":"HR POS","children":[{"content":"NO LINE","children":[{"content":"<strong>MA39</strong>","children":[{"content":"Newly Diagnosis of IDC w/ no metastisis Treated with BCS or Mastectomy with no residual disease","children":[],"payload":{"lines":"111,112"}}],"payload":{"lines":"110,112"}}],"payload":{"lines":"109,112"}}],"payload":{"lines":"108,112"}}],"payload":{"lines":"107,112"}}],"payload":{"lines":"106,112"}},{"content":"SURG ONC","children":[{"content":"Peri-Surgical","children":[{"content":"NO GROUP","children":[{"content":"NO LINE","children":[{"content":"<strong>CHEST</strong>","children":[{"content":"Undergoing Mastectomy + Reconstruction","children":[],"payload":{"lines":"117,118"}}],"payload":{"lines":"116,118"}},{"content":"<strong>Breast ATLAS</strong>","children":[{"content":"Undergoing PPX Mastectomy","children":[],"payload":{"lines":"119,120"}}],"payload":{"lines":"118,120"}},{"content":"<strong>PRECISION</strong>","children":[{"content":"Dx of DCIS and/or IDC undergoing BCS or mastectomy 2) No hx of prior therapy treatment","children":[],"payload":{"lines":"121,122"}}],"payload":{"lines":"120,122"}},{"content":"<strong>SentiNot 2.0</strong>","children":[{"content":"Pre-operative diagnosis of DCIS or other suspicious lesion not confirmed to be invasive breast cancer 2) Willing to forgo initial SLNB and have SLNB as a later second procedure if DCIS is upgraded to invasive cancer","children":[],"payload":{"lines":"123,124"}}],"payload":{"lines":"122,124"}},{"content":"<strong>Magellan</strong>","children":[{"content":"Non-metastatic patients with node positive breast cancer (cT0-4, N1) 2) Magseed placement prior to NAC","children":[],"payload":{"lines":"125,126"}}],"payload":{"lines":"124,126"}}],"payload":{"lines":"115,126"}}],"payload":{"lines":"114,126"}}],"payload":{"lines":"113,126"}},{"content":"Postsurgical","children":[{"content":"NO GROUP","children":[{"content":"NO LINE","children":[{"content":"<em>PREDICT II</em>","children":[{"content":"Dx of DCIS w/ tumor size &lt;6cm * Eligible for BCS, radiation and/or systemic treatment","children":[],"payload":{"lines":"130,131"}}],"payload":{"lines":"129,131"}}],"payload":{"lines":"128,131"}}],"payload":{"lines":"127,131"}}],"payload":{"lines":"126,131"}},{"content":"Presurgical","children":[{"content":"NO GROUP","children":[{"content":"NO LINE","children":[{"content":"<strong>ATUSA-iSONO</strong>","children":[{"content":"Women with a suspected breast lesion in one of both breasts 2) Disease T1c or larger","children":[],"payload":{"lines":"135,136"}}],"payload":{"lines":"134,136"}},{"content":"<strong>BCM TISSUE COLLECTION</strong>","children":[{"content":"Suspicious lesion receiving an U/S guided biopsy with birads 4b-5","children":[],"payload":{"lines":"137,138"}}],"payload":{"lines":"136,138"}},{"content":"<strong>ANGEL</strong>","children":[{"content":"Any suspicious lesion receiving a biopsy","children":[],"payload":{"lines":"139,140"}}],"payload":{"lines":"138,140"}}],"payload":{"lines":"133,140"}}],"payload":{"lines":"132,140"}}],"payload":{"lines":"131,140"}}],"payload":{"lines":"112,140"}},{"content":"UPCOMING","children":[{"content":"Neoadjuvant","children":[{"content":"HR POS","children":[{"content":"NO LINE","children":[{"content":"<em>CDK4i PF0060</em>","children":[{"content":"T1 to T3, with smallest size 15mm. Any N. Excludes T4 and N3","children":[],"payload":{"lines":"145,146"}}],"payload":{"lines":"144,146"}}],"payload":{"lines":"143,146"}}],"payload":{"lines":"142,146"}}],"payload":{"lines":"141,146"}}],"payload":{"lines":"140,146"}}],"payload":{"lines":"0,146"}}, {"initialExpandLevel":3});
})();
</script>
</body>
</html>
